30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
BackgroundAccurate and accessible risk assessment tools are essential for effective dementia management. 3 key findings →
Design: longitudinal study Participants: 27,768 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
74,396 patients (median age 84, IQR 78-89; 68% female) were analyzed. 5 key findings →
Design: cohort study Participants: 74,396 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified a total of 1,686,759 patients with incident dementia (mean (SD) age, 82.15 (6.90) years; 61.70% female) and 3,373,518 matched controls (mean (SD) age, 82.15 (6.90) years; 61.70% female). 5 key findings →
Design: cohort study Participants: 1,686,759 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
NPS were highly prevalent (≥90%) in early and late bvFTD. 5 key findings →
Design: longitudinal study Participants: 354 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Eighty older adults with MCI (median age 86.50 years) participated, with an average attendance rate of 86.25% in the intervention group. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
(n = 16,683) had an average age of 69.07 ± 7.34, 72.04% were female, and had an average of 16.66 ± 2.26 years of education. 5 key findings →
Design: longitudinal study Participants: 16,683 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In 2018, Carlos et al. [2] reviewed 21 studies from the SUN project that focused on the association between the MDP and several incident chronic diseases, concluding that high Mediterranean diet adherence was associated with a lower incidence of all-cause mortality, cardiovascular disease, type 2 diabetes, weight gain, metabolic syndrome, depression, cognitive decline, and nephrolithiasis, and with a lower heart rate and mitigation of the effects of obesity on cardiovascular disease (CVD) and type 2 diabetes, and our results suggested that the Mediterranean diet may improve fertility. 5 key findings →
Design: cohort study Participants: 79 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among all participants, 247 (11.7%) had IADL limitations at baseline, and 151 (7.1%) developed dementia during follow-up. 5 key findings →
Design: longitudinal study Participants: 2,118 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
CogDrisk-ML outperformed CAIDE in the UK Biobank and Whitehall II cohorts; however, it provided similar C statistics in the ARIC dataset. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Data collection commenced in November 2023 and finished in July 2024, with the enrollment of 49 older adults with MCI (n=40, 81.6%, assigned to the experimental group [EG] and n=9, 18.4%, to the control group [CG]) conducted from October 2023 to April 2024. 5 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The CITA GO-ON Study, as a part of the World-Wide FINGERS network, is designed to validate the efficacy of a multidomain lifestyle intervention for dementia prevention and contribute valuable data to inform public health strategies fostering healthy, active aging. 3 key findings →
Design: randomized controlled trial Participants: 1,051 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We identified 1143 dementia-free individuals with acute stroke during follow-up: 1061 (92.8%) ischemic, 82 (7.2%) hemorrhagic, 49.9% female, and 30.8% Black. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neuro-inflammation was not reduced between the neflamapimod and placebo groups, and no change was observed in [18F]-DPA-714 PET. 5 key findings →
Design: randomized controlled trial Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 298 participants (MCI, n = 56; NC, n = 242; mean age 75.1 years; 45.6% female), the groups were similar in age, sex, race, and APOE ε4 status at baseline, as well as in most driving behaviors. 4 key findings →
Design: cohort Participants: 298 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
In the intention-to-treat analysis, dementia risk was not different between GLP1-RA and DPP4i initiators (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.87–1.04; rates: 6.29 versus 6.64 per 1000 person-years; mean follow-up: 6.54 years); however, continuous GLP1-RA versus DPP4i use was associated with a 21% lower risk (HR 0.79, 95% CI 0.64–0.97; rates: 3.64 versus 4.82; mean follow-up: 2.71 years). 4 key findings →
Design: cohort Participants: 107,424 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma GFAP is a prognostic biomarker in CU older adults, predicting cognitive and biological changes, with stronger associations observed in females, highlighting a possible sex-specific vulnerability. 5 key findings →
Design: cohort Participants: 949 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest EPVS burden to be a potential marker of both CSVD and AD-related BBM pathology. 3 key findings →
Design: cross-sectional Participants: 979 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mean (SD) β-glucocerebrosidase levels were higher at week 26 (ambroxol, 12.45 [1.97] nmol/h/mg; 91% CI, 11.54-13.36 nmol/h/mg); placebo, 8.50 [1.96] nmol/h/mg; 91% CI, 7.65-9.34 nmol/h/mg; P = .05) in the ambroxol group compared with placebo. 3 key findings →
Design: clinical trial Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The APOE ε4 genetic variant is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and is increasingly being implicated in other neurodegenerative diseases. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
However, a recent systematic review and meta-analysis did not support differences in orexin-A between AD and controls. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 413 477 All of Us participants, 2038 were eligible. 5 key findings →
Design: cohort study Participants: 26 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Uncertainty remains regarding the role of diet in colorectal cancer development. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
14 IPD-Work studies were assessed and six studies were excluded due to missing outcome data and unavailable data for pooling, resulting in the inclusion of eight studies with 124 909 participants. 5 key findings →
Participants: 909 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The overall PAF for the 14 modifiable risk factors was 59.5% (95% CI = 58.5-60.5). 5 key findings →
Design: longitudinal study Participants: 9,949 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events